SELLAS Life Sciences Group, Inc. (SLS): Price and Financial Metrics


SELLAS Life Sciences Group, Inc. (SLS): $2.98

0.15 (+5.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SLS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SLS POWR Grades


  • Value is the dimension where SLS ranks best; there it ranks ahead of 59.01% of US stocks.
  • SLS's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • SLS's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

SLS Stock Summary

  • The ratio of debt to operating expenses for SELLAS Life Sciences Group Inc is higher than it is for about merely 8.1% of US stocks.
  • SLS's price/sales ratio is 11.94; that's higher than the P/S ratio of 87.74% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SLS comes in at -31.47% -- higher than that of only 12.57% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to SELLAS Life Sciences Group Inc are SINT, MNDO, SLRX, HSTO, and FKWL.
  • Visit SLS's SEC page to see the company's official filings. To visit the company's web site, go to www.sellaslifesciences.com.

SLS Valuation Summary

  • In comparison to the median Healthcare stock, SLS's price/earnings ratio is 126.58% lower, now standing at -9.7.
  • SLS's EV/EBIT ratio has moved up 4.1 over the prior 164 months.
  • SLS's price/sales ratio has moved NA NA over the prior 164 months.

Below are key valuation metrics over time for SLS.

Stock Date P/S P/B P/E EV/EBIT
SLS 2021-08-31 15.5 4.4 -9.7 -7.8
SLS 2021-08-30 15.4 4.4 -9.6 -7.7
SLS 2021-08-27 15.6 4.4 -9.7 -7.8
SLS 2021-08-26 15.4 4.4 -9.6 -7.7
SLS 2021-08-25 15.4 4.4 -9.6 -7.7
SLS 2021-08-24 15.6 4.4 -9.8 -7.8

SLS Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -92.34%.
  • Its year over year cash and equivalents growth rate is now at 310.94%.
  • Its 4 year net cashflow from operations growth rate is now at 60.89%.
SLS's revenue has moved up $9,500,000 over the prior 15 months.

The table below shows SLS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 9.5 -17.621 -17.817
2021-06-30 9.5 -15.372 -15.205
2021-03-31 7.6 -13.855 -15.017
2020-12-31 1.9 -10.417 -16.835
2020-09-30 0 -18.017 -20.538
2020-06-30 0 -18.208 -27.535

SLS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SLS has a Quality Grade of D, ranking ahead of 22.65% of graded US stocks.
  • SLS's asset turnover comes in at 0.255 -- ranking 173rd of 680 Pharmaceutical Products stocks.
  • ZSAN, MNOV, and OVID are the stocks whose asset turnover ratios are most correlated with SLS.

The table below shows SLS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.255 0.979 -3.728
2021-03-31 0.254 0.987 -4.352
2020-12-31 0.079 1.000 -5.135
2020-09-30 0.000 NA -4.595
2020-06-30 0.000 NA -4.552
2020-03-31 0.000 NA -4.415

SLS Price Target

For more insight on analysts targets of SLS, see our SLS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.50 Average Broker Recommendation 1.5 (Moderate Buy)

SLS Stock Price Chart Interactive Chart >

Price chart for SLS

SLS Price/Volume Stats

Current price $2.98 52-week high $15.08
Prev. close $2.83 52-week low $2.10
Day low $2.86 Volume 143,100
Day high $3.02 Avg. volume 225,589
50-day MA $4.28 Dividend yield N/A
200-day MA $6.73 Market Cap 61.20M

SELLAS Life Sciences Group, Inc. (SLS) Company Bio


SELLAS Life Sciences, Ltd. is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.


SLS Latest News Stream


Event/Time News Detail
Loading, please wait...

SLS Latest Social Stream


Loading social stream, please wait...

View Full SLS Social Stream

Latest SLS News From Around the Web

Below are the latest news stories about SELLAS Life Sciences Group Inc that investors may wish to consider to help them evaluate SLS as an investment opportunity.

Sellas, Merck complete enrollment in GPS-Keytruda combo phase 1/2 trial in ovarian cancer

Sellas Life Sciences (SLS +0.9%) completed enrollment in a phase 1/2 trial of its lead asset galinpepimut-S (GPS) in combination with Merck’s (MRK +0.1%) Keytruda (pembrolizumab) in second or third line Wilms Tumor-1 (WT1)(+) relapsed or refractory metastatic ovarian cancer. The total expected enrolled and evaluable number of patients is 17....

Seeking Alpha | February 1, 2022

SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final Data for up to 17 Patients in Q4 2022 NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced t

Yahoo | February 1, 2022

Sellas Life Sciences'' IND application for galinpepimut-S accepted in China

SELLAS Life Sciences Group (SLS) announces that an IND application to initiate the first clinical trial in China for 3D189, also known as galinpepimut-S ((GPS)), has been accepted

Seeking Alpha | January 27, 2022

SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response After Receiving Standard TreatmentNEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that an IND application to initiate the

Yahoo | January 27, 2022

SELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer

NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T. Burns has been promoted within the Company to Senior Vice President, Finance, and Chief Accounting Officer. “John is an invaluable member of our small, yet nimble SELLAS team. He consistently demonstrates his expertise

Yahoo | January 5, 2022

Read More 'SLS' Stories Here

SLS Price Returns

1-mo N/A
3-mo -54.50%
6-mo -56.62%
1-year -66.25%
3-year -92.55%
5-year -99.65%
YTD -46.11%
2021 -4.82%
2020 35.12%
2019 -93.01%
2018 -84.23%
2017 -86.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7651 seconds.